IDEXX Laboratories, Inc. 2. Çeyrek 2026 Kazanç Çağrı Özeti

IDEXX Laboratories, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Wed, August 5, 2026 at 1:15 AM GMT+3 3 min read

• IDXX -0.56%

Strategic Performance Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Performance was anchored by 10.3% organic growth in CAG Diagnostics recurring revenue, significantly outpacing a 1.3% decline in U.S. same-store clinical visits.

• Management attributes the growth premium to 'visit quality,' where diagnostic intensity per visit is increasing despite macro-driven pressure on discretionary wellness visits.

• The aging pet population (pets 5+) is a structural tailwind, as these animals require higher diagnostic frequency for both wellness and chronic care management.

• International momentum remains robust with nearly 12% organic recurring revenue growth, driven by net new customer gains and expanded instrument utilization.

• Innovation adoption is accelerating, with inVue Dx reaching 9,000 total placements since launch and Cancer Dx surpassing 10,000 ordering clinics globally.

• Strategic integration of software (Vello/ezyVet) and diagnostics is driving higher wellness bloodwork inclusion rates compared to practices on competitive legacy systems.

• Operating margin expansion of 110 basis points was fueled by favorable product costs and a high-margin mix of recurring consumables and reference lab volumes.

Outlook and Strategic Assumptions

• Full-year organic revenue growth guidance was raised to 8.5%-9.7%, reflecting confidence in global recurring revenue momentum despite a $15 million FX headwind.

• Guidance assumes U.S. clinical visits will remain pressured, with an anticipated 1.5% decline in the second half of 2026.

• Management is accelerating commercial investments, expanding field presence in four international markets and the U.S. to drive long-term sector development.

• The inVue Dx platform is expected to reach 5,500 total placements for the year, supported by the broad commercial rollout of Fine Needle Aspirate (FNA) capabilities by year-end.

• Cancer Dx is slated to expand into a multi-cancer panel in late Q3 with the addition of mast cell tumor detection at no incremental cost to customers.

Operational Risks and Structural Shifts

• Instrument revenues declined 20% organically, a planned result of lapping the prior year's broad commercial availability of the inVue Dx platform.

• Wellness visits remain the primary constraint on clinical volume, down 3.4% in the U.S., which management attributes to broader inflationary pressures on consumers.

• Foreign exchange volatility is expected to create a 70 basis point headwind to reported revenues in the third quarter.

• Incremental R&D and commercial spending in the second half will result in more modest operating margin expansion of 20-50 basis points in Q3.

Q&A Session Highlights

Rollout and consumable flow-through of inVue Dx FNA

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

• Consumable revenue per inVue instrument is tracking within the expected $3,500 to $5,500 range.

• FNA is currently in a controlled launch to optimize customer experience, with a meaningful expansion planned for Q3 and full availability by year-end.

• Early data suggests the slide-free workflow is increasing the total number of masses evaluated in-clinic due to reduced cost and complexity.

Sustainability of Reference Lab growth and market share

• Reference Lab growth reached double digits for the first time since early 2023, driven by innovation like Cancer Dx and Fecal Dx expansions.

• Approximately 20% of Cancer Dx orders are coming from practices that otherwise use competitive labs, serving as a 'trojan horse' for full lab conversions.

• Management dismissed concerns over long-term visit erosion, citing massive headroom in wellness bloodwork inclusion (currently only 1 in 10 U.S. visits).

Strategic rationale for SDMA integration into Catalyst CLIPs

• Moving SDMA into standard chemistry CLIPs at the point of care streamlines workflow and inventory for veterinarians.

• Management does not expect cannibalization of Reference Lab volumes, as point-of-care testing typically addresses acute/sick pet use cases while labs handle routine screening.

• The integration helps identify up to one-third more renal dysfunction cases than creatinine testing alone.

Capacity to manage multiple simultaneous instrument launches

• Management expressed high confidence in commercial bandwidth to support both inVue Dx and future platforms like Multi-Q.

• The strategy relies on a proven playbook of territory sizing and field education to help clinics integrate new technologies into daily protocols.